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Impaired platelet activation in patients with hereditary
deficiency of p47phox
Chronic granulomatous disease (CGD) is a rare primary
immunodeficiency affecting the innate immunological sys-
tem, which is characterized by impaired reactive oxidant spe-
cies (ROS) generation and, eventually, defective bacteria
killing (van den Berg et al, 2009). NADPH oxidase (Nox)2
(also termed CYBB) hereditary deficiency (X-linked CGD) is
the most frequent form of CGD and is complicated by life-
threatening infections (Martire et al, 2008); conversely,
hereditary deficiency of the p47phox subunit (also termed
NCF1) is less frequent and characterized by partial ROS gen-
eration impairment and milder infectious disease (Kuhns
et al, 2010).
Experimental and clinical studies demonstrated that Nox2
is expressed in platelets and exerts pro-thrombotic effects via
isoprostane formation and/or nitric oxide (NO) generation
inhibition (Pignatelli et al, 2011; Carnevale et al, 2014a). So
far, no data have been reported on platelet activation beha-
viour in patients with p47phox hereditary deficiency. Analysis
of platelet behaviour in this setting might be useful to assess
if, as compared to Nox2 deficiency, a less marked impair-
ment of oxidative stress, as detected in patients with heredi-
tary deficiency of p47phox, is also associated with lowered
platelet activation.
This study was performed in collaboration with the Italian
Primary Immuno-deficiencies Network. Two researchers vis-
ited to each centre at different times to take blood. Fifteen
CDG patients (10 X-CGD and 5 with p47phox hereditary defi-
ciency), and 10 healthy subjects (HS), matched for age and
sex, were recruited. CGD was diagnosed as previously
described (Martire et al, 2008). CGD patients were excluded
in case of acute infection, critical physical condition or
unwillingness to participate in the study. All patients with
CGD were under treatment with itraconazole, trimethoprim
and sulfamethoxazole. HS were screened at routine visits.
Subjects were excluded from the study if they had liver insuf-
ficiency, serious renal disorder (serum creatinine
>2475 lmol/l), cancer, myocardial infarction, unstable ang-
ina, acute cerebrovascular disease, deep venous thrombosis
or were being treated with statins, antioxidant, vitamins or
antiplatelet drugs or if they were current smokers. The study
was conformed to the declaration of Helsinki and approved
by the Ethical Committee of Sapienza University of Rome.
For each patient and control fasting period of at least
12 h, platelet poor plasma and platelet rich plasma (PRP)
were prepared as previously described (Carnevale et al,
2014b). Plasma levels of glycoprotein IIb/IIIa (GPIIb/IIIa,
also known as integrin aIIbb3, ITGA2B) and soluble CD40
ligand (sCD40L) were measured with use of a commercial
immunoassay (Abcam, Cambridge, UK; DRG International,
Marburg, Germany). Platelet production of NO and H2O2 by
collagen (4 lg/ml)-stimulated PRP was measured by colouri-
metric assay (Arbor Assays, Ann Arbor, MI, USA).
Distribution of variables was assessed by Kolmogorov–
Smirnov test. Categorical variables are reported as number
and percentage, continuous variables as means  standard
deviation unless otherwise indicated. Independence of cate-
gorical variables was tested by chi-square test. Comparisons
between the three groups (i.e. X-CGD patients, p47phox-defi-
cient patients and HS) were analysed by Mann–Whitney test.
A value of P < 005 was considered statistically significant.
All analyses were performed with SPSS V.18.0 (SPSS Statistics
v. 18.0, SPSS Inc., Chicago, IL, USA).
As previously reported, there were no differences in terms
of age, gender and risk factors of atherosclerosis between
CGD and HS. None of the CGD patient had a clinical his-
tory of bleeding. Table I reports the distribution of antibiotic
treatment between X-CGD and p47phox.
Compared to HS, X-CGD patients had lower platelet acti-
vation as shown by reduced plasma levels of GPIIb/IIIa and
sCD40L (Fig 1A–B). Compared to patients with p47phox defi-
ciency, X-CGD patients had lower levels of GPIIb/IIIa and
sCD40L (Fig 1A–B). In the overall population, bivariate anal-
ysis showed a significant correlation between sCD40L and
GPIIb/IIIa levels (Rs 0694, P < 00001).
Table I. Subject characteristics.
X-CGD (n = 10)
HS
(n = 10)
p47phox
deficiency
(n = 5)
Age, years 17  5 17  5 17  5
Male, n 0 1 1
Treatment,
n
Itraconazole,
trimethoprim
and sulfamethoxazole,
10
– Itraconazole,
trimethoprim
and
sulfamethoxazole,
5
X-CGD, X-linked chronic granulomatous disease; HS, healthy sub-
jects.
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Ex-vivo studies showed that, compared to HS, CGD
patients had lower platelet H2O2 production and higher NO
bioavailability (Fig 1C–D). Compared to patients with
p47phox deficiency, X-CGD patients had significantly lower
platelet H2O2 and higher platelet NO (Fig 1C–D).
The study provides the first evidence that CGD patients
with hereditary deficiency of p47phox display reduced platelet
activation in vivo and ex vivo, further reinforcing the pivotal
role of ROS in platelet activation.
This study compared two CGD groups with marked
(Nox2 deficiency) and less marked (p47phox deficiency) ROS
formation. Both groups showed reduced sCD40L and GPIIb/
IIIa circulating levels compared to controls but impairment
of platelet activation was greater in patients with hereditary
Nox2 deficiency. In accordance with our hypothesis, this
behaviour may be attributed to the different impaired plate-
let production of oxidant species, such as H2O2, which, in
fact, was more seriously compromised in X-CGD compared
to hereditary p47phox deficiency. In this regard, it is
noteworthy that H2O2 serves to activate platelets via intracel-
lular calcium mobilization and, in turn, thromboxane A2-
dependent and -independent mechanisms (Pignatelli et al,
2011). Experiments in animals over-expressing glutathione
peroxidase 1, which degrades H2O2, further supported the
role for this oxidant species in eliciting platelet-related
thrombosis (Dayal et al, 2013). Enhanced NO generation
may be another mechanism accounting for platelet inhibition
in both CGD groups; thus, impaired superoxide production
results in lower inhibition of biosynthesis and/or activity of
NO, which is a powerful antiplatelet molecule (Carnevale
et al, 2014a).
The study has limitation and potentially clinical implica-
tion. The small sample size of p47phox deficient group is a
limitation; however, recruitment of these patients is difficult
as the prevalence of p47phox hereditary deficiency is more
rare than X-CGD prevalence (1:250 000) (Winkelstein et al,
2000). Even if experimental studies suggest Nox2 as a novel
target for antiplatelet treatment, its inhibition should be
Fig 1. Platelet activation. Plasma levels of glycoprotein IIb/IIIa (IIb/IIIa) (A) and soluble CD40 ligand (sCD40L) (B) in healthy subjects (HS,
n = 10), X-linked chronic granulomatous disease (X-CGD) (n = 10) and p47phox deficiency (n = 5). Platelet H2O2 production (C) and NO
bioavailability (D) levels in HS (n = 10), X-CGD (n = 10) and p47phox deficiency (n = 5). *P < 0005, **P < 005.
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carefully considered for the potentially negative effects in
innate immune system and bacterial killing (Delaney et al,
2016). Inhibition of p47phox, which contributes to Nox2 acti-
vation along with the other cytosolic subunits, may be an
interesting alternative as indicated by a less negative impact
on the innate immune system by p47phox deficiency (Lof-
fredo et al, 2013). Furthermore, pharmacological intervention
with apocynin, which inhibits p47phox assembly to Nox2,
demonstrated an antiplatelet effect in experimental
atherosclerosis. Of note, none of the patients included in the
study had a clinical history of bleeding.
In conclusion, patients with hereditary p47phox deficiency
show reduced platelet activation suggesting a role for this
Nox cytosolic subunit in platelet activation.
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